Verastem Oncology has reported that its combination therapy for pancreatic cancer led to an 86% overall survival rate in a clinical trial, according to a report from Clinical Trials Arena. The findings represent a potential step forward for patients with this aggressive cancer. This article summarizes what is known from that report so far.

  • The combination therapy involves two investigational drugs: a RAF/MEK inhibitor and a FAK inhibitor.
  • In the trial, 86% of patients were alive at the point of analysis, though the exact follow-up period is not specified in the report.
  • Pancreatic cancer is among the most lethal cancers, with a five-year survival rate of about 12 percent.
  • These results are early and should be confirmed in larger, randomized studies.

What is the combination therapy?

The treatment combines two targeted agents: VS-6766, a RAF/MEK inhibitor, and defactinib, a FAK inhibitor. Both drugs are designed to block signaling pathways that help cancer cells grow and survive. In preclinical models, the combination showed synergistic activity against pancreatic cancer cells. The trial enrolling patients is likely a phase 1 or 2 study, though the report from Clinical Trials Arena did not provide the exact phase or number of participants.

Trial results and significance

The headline result is an 86% overall survival rate. Overall survival (OS) measures the percentage of patients still alive after a certain time, often at one year or another pre-specified point. This rate is higher than what is typically seen with standard chemotherapy for advanced pancreatic cancer. However, without more details on the patient population, stage of disease, and duration of follow-up, it is difficult to compare directly with other studies. The report emphasizes that these data are preliminary.

Potential implications for patients

If future trials confirm these results, the combination could become a new option for patients with pancreatic cancer. Current standard treatments include chemotherapy regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel. Targeted therapies are an active area of research because they may offer more effective and less toxic alternatives. Patients should discuss any investigational treatments with their oncology team and consider enrolling in clinical trials if eligible.

What comes next

Verastem Oncology is likely to present more detailed data at an upcoming medical conference and to plan a larger randomized trial. Regulatory discussions may follow if the evidence supports a benefit over current care. The company has not yet announced a timeline for these steps. Until then, the 86% overall survival rate should be interpreted cautiously as an early signal of promise.

Frequently Asked Questions

What is overall survival and why is it important?

Overall survival (OS) is the length of time from the start of treatment that patients remain alive. It is considered the gold standard endpoint in cancer trials because it directly measures a benefit that matters to patients. An 86% OS rate suggests that most patients in the trial were still alive at the time of assessment, though the exact time point is not reported.

Is this combination therapy approved for pancreatic cancer?

No, neither VS-6766 nor defactinib is approved for pancreatic cancer. They are investigational drugs being tested in clinical trials. The latest data are preliminary and have not been reviewed by regulators such as the U.S. Food and Drug Administration (FDA). Approval would require positive results from larger, confirmatory trials.

How can patients learn more or potentially access this treatment?

Patients interested in this combination should speak with their oncologist about clinical trial options. Verastem Oncology may be enrolling additional studies. Information can be found on ClinicalTrials.gov by searching for VS-6766 and defactinib in pancreatic cancer. Availability is limited to trial sites and eligibility criteria apply.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.